Artificial intelligence continues to transform biotechnology with pioneering advances in protein engineering and drug discovery. The AlphaDesign framework, leveraging AlphaFold’s capabilities, enables de novo protein creations tailored for specific functions, accelerating therapeutic development. Companies like Insilico Medicine utilize generative chemistry platforms to discover novel KRAS inhibitors, previously considered undruggable targets. Additionally, AI-driven virtual cell models now facilitate detailed perturbation analyses at single-cell resolution, enhancing target identification and guiding drug development with unprecedented precision.